Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support
India’s institutions now need to upgrade TTOs as strategic innovation units rather than administrative support cells
The private funding rose 38% amid growing international collaborations and CDMO demand
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
The investment will bring in cutting-edge downstream fermentation technology, strengthening the company’s contract manufacturing capabilities for drug substances
Postdoctoral fellowship aims to build skilled talent pool in biotechnology and life sciences
Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
Nature Medicine study delivers strongest real-world evidence yet for India’s indigenous rotavirus vaccine under UIP
Subscribe To Our Newsletter & Stay Updated
